Investment accounts
Adult accounts
Child accounts
Choosing Fidelity
Choosing Fidelity
Why invest with us Current offers Fees and charges Open an account Transfer investments
Financial advice & support
Fidelity’s Services
Fidelity’s Services
Financial advice Retirement Wealth Management Investor Centre (London) Bereavement
Guidance and tools
Guidance and tools
Choosing investments Choosing accounts ISA calculator Retirement calculators
Share dealing
Choose your shares
Tools and information
Tools and information
Share prices and markets Chart and compare shares Stock market news Shareholder perks IPOs and placings
Pensions & retirement
Pensions, tax & tools
Saving for retirement
Approaching / In retirement
Approaching / In retirement
Speak to a specialist Creating a retirement plan Taking tax-free cash Pension drawdown Annuities Investing in retirement Investment Pathways
Braveheart to retain Paraytec after failing to find buyer
(Sharecast News) - Braveheart Investment Group updated the market on one of its key investments, Paraytec, on Monday, confirming that it had failed to find an appropriate buyer for the company. The AIM-traded firm had announced on 15 December that it had engaged a merger and acquisition specialist to pursue a cash buyer for Paraytec.
Despite an extensive marketing campaign, the company said it had not received satisfactory offers from potential acquirers.
As a result, the board said it had resolved to retain Paraytec within its investment portfolio.
Paraytec would continue its efforts to enhance the sales and marketing of its CX300 instrument and associated consumables.
The overarching goal, Braveheart explained, remained to augment its attractiveness to potential acquirers or partners in the future.
Braveheart maintained full ownership of Paraytec, holding a 100% equity interest and having extended unsecured interest-free loans to Paraytec totalling £1.26m as of 30 September.
"As previously reported, Paraytec is working on the development of the CX300 instrument to assist in the rapid diagnosis and treatment of bacteraemia, the presence of bacteria in the blood, which is found in the majority of patients with sepsis," the Braveheart board said in its announcement.
"Paraytec has also developed technical notes on how the CX300 can be used for the detection of protein aggregation, an important factor for protein producers and users, and adeno-associated virus which are used in gene therapy.
"Three universities have signed sales contracts, two for use in their work on extracellular vesicles, with others showing interest in that area."
At 1412 GMT, shares in Braveheart Investment Group were down 5.62% at 7.55p.
Reporting by Josh White for Sharecast.com.
Share this article
Related Sharecast Articles
Important information: This information is not a personal recommendation for any particular investment. If you are unsure about the suitability of an investment you should speak to one of Fidelity’s advisers or an authorised financial adviser of your choice. When you are thinking about investing in shares, it’s generally a good idea to consider holding them alongside other investments in a diversified portfolio of assets. Past performance is not a reliable indicator of future returns.
Award-winning online share dealing
Search, compare and select from thousands of shares.
Expert insights into investing your money
Our team of experts explore the world of share dealing.
Policies and important information
Accessibility | Conflicts of interest statement | Consumer Duty Target Market | Consumer Duty Value Assessment Statement | Cookie policy | Diversity and Inclusion | Doing Business with Fidelity | Fidelity gender pay report | Investing in Fidelity funds | Legal information | Modern slavery | Mutual respect policy | Privacy statement | Remuneration policy | Security | Statutory and Regulatory disclosures | Whistleblowing policy
Please remember that past performance is not necessarily a guide to future performance, the performance of investments is not guaranteed, and the value of your investments can go down as well as up, so you may get back less than you invest. When investments have particular tax features, these will depend on your personal circumstances and tax rules may change in the future. This website does not contain any personal recommendations for a particular course of action, service or product. You should regularly review your investment objectives and choices and, if you are unsure whether an investment is suitable for you, you should contact an authorised financial adviser. Before opening an account, please read the ‘Doing Business with Fidelity’ document which incorporates our client terms. Prior to investing into a fund, please read the relevant key information document which contains important information about the fund.
This website is issued by Financial Administration Services Limited, which is authorised and regulated by the Financial Conduct Authority (FCA) (FCA Register number 122169) and registered in England and Wales under company number 1629709 whose registered address is Beech Gate, Millfield Lane, Lower Kingswood, Tadworth, Surrey, KT20 6RP.